On page 8, please amend the paragraph beginning on line 7 as follows:

As one skilled in the art would recognize, the modified TNF of this invention may be administered in a number of ways, for example, orally, intranasally, intraperitoneally, parenterally, intravenously, intralymphatically, ~~intratumorly~~ intratumorally, intramuscularly, interstitially, intrarterially, subcutaneously, intraocularly, ~~intrasynoially~~ intrasynovially, transepithelially, and transdermally. A therapeutically effective amount of one of the modified compounds of the present invention is an amount effective to inhibit tumor growth, and that amount may vary according to the method of administration. Generally, effective doses should be in the range of about 0.001 to 0.1 mg/kg, once a week. The modified TNF may be formulated with pharmaceutically acceptable carriers and diluents, as known in the art. For example, for ~~intravenous?~~ intravenous administration, the modified TNF may be mixed with a phosphate buffered saline solution, or any other appropriate solution known to those skilled in the art, prior to injection. Tests have shown that the modified TNF is particularly effective in treating melanoma, colon cancer, kidney cancer and breast cancer tumors.

Please amend the paragraph on page 8, beginning on line 23 as follows:

TNF used in the experiments described below was of mouse TNF and human TNF or human TNF mutants. The human TNF was produced in *E. coli* ~~*and Pichea pasatoris*~~ and *Pichia pastoris*, and murine TNF as well as human TNF mutants were produced in ~~*Pichea*~~ *Pichia pastoris*. Recombinant TNF was produced in *E. coli* or ~~*Pichea*~~ *Pichia* using methods similar to those described in Pennica, D., et al., *Nature*, **312**:724-729 (1981); Streekishna, K., et al., *Biochemistry*, **28**:4117-4125 (1989). The mouse TNF was produced in *E. coli* and in ~~*Pichea*~~ *Pichia*.